The social context of drinking among LGBT+ people
Professor Carol Emslie and David Barbour discuss research on gender, identity and drinking, and the disproportionate impact of substance use in the LGBT+ community.
Professor Carol Emslie and David Barbour discuss research on gender, identity and drinking, and the disproportionate impact of substance use in the LGBT+ community.
In this research, the authors explored how lesbian, gay, bisexual, transgender, and queer (LGBTQ) young adults with problematic substance use made sense of their substance use in relation to their LGBTQ identities.
The authors interviewed...
This briefing provides a summary of alcohol consumption, alcohol harm, alcohol treatment, and gaps in knowledge regarding alcohol use among LGBTQ+ people.
It uses the acronym LGBTQ+ to include lesbian, gay, bisexual, transgender, queer...
Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ+) Pride month is celebrated each year during the month of June. Here you can find a list of resources and research on the topic of substance use among the LGBTQ+ community.
1) This repor...
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national...
Navzdory rozsáhlým důkazům o negativních účincích stigmatu, které zažívají lidé žijící s HIV (PLHIV) a lidé, kteří si drogy aplikují injekčně ve zdravotnických zařízeních, existuje poměrně málo důkazů o účinnosti iniciativ na snížení tohoto...
Alcohol and other drug treatment are generally only provided for individuals, often away from their families. Treatment aims to improve well-being and reduce the harms of substance use and families and communities can play a significant...
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
Substance use disorders (SUDs) are highly prevalent and impact individuals' health, well-being, and social functioning. Long-lasting changes in brain networks involved in reward, executive function, stress reactivity, mood, and...
Presented by Richard Rawson, PhD, Emeritus Professor in the Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine and a Research Professor at the University of Vermont, this presentation provided an overview of the...
In the magazine CIJ Informa, the participation of CIJ, host chapter institution of ISSUP Mexico, in the 71st Regular Session of CICAD is reviewed.
The Anti-Stigma Network has been launched!
The Anti-Stigma Network has been created by a group of organisations coming together with a shared mission.
Collectively they aim to improve understanding of the stigma and...
Background
Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment. Methadone and...
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...
Question What treatments for cocaine use disorder are associated with objective reductions in cocaine use among adults?
Findings In this meta-analysis of 157 clinical trials comprising 402 treatment groups and 15 842...
Kokain je návyková stimulační droga, která pochází z listů rostliny koky, která pochází z Jižní Ameriky. Mezi účinky léku patří zvýšená bdělost, pozornost a energie, stejně jako pocity euforie a důvěry. Tyto účinky jsou však spojeny s...
The markets for hexahydrocannabinol (HHC) and related semi-synthetic cannabinoids (SSC) are rapidly evolving areas with relatively limited information currently available.
The European situation presented in Section 1 can...
Objective: To better understand current developments in the treatment of stimulant use.
Background: Stimulant drugs are second only to cannabis as the most widely used class of illicit drug globally, accounting for 68 million past-year...